Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shionogi-ViiV

- PMLiVE

GSK gets another approval for Nucala in US

Its antibody is first approved treatment for a rare and sometimes life-threatening vascular disease

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

- PMLiVE

ViiV starts trial of HIV-preventing injections for women

Cabotegravir could provide a new way for women to protect themselves

- PMLiVE

Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial

Fails late-stage stomach cancer study

Pfizer names Albert Bourla as COO

John Young and Angela Hwang also take up new positions at the pharma firm

- PMLiVE

GSK’s ViiV gets US okay for two-drug HIV regimen

Juluca is a combination of ViiV’s Tivicay and Janssen’s Edurant

- PMLiVE

Sutent gets FDA approval for early use in kidney cancer

Decision could help Pfizer combat competition from BMS' Opdivo and Yervoy

- PMLiVE

EMA approves GSK’s triple COPD therapy

Trelegy can now be marketed as a maintenance treatment in Europe

National Institute for Health and Care Excellence NICE logo

NICE backs two advanced breast cancer drugs after price cuts

An estimated 8,000 women will be eligible to receive the drugs due to discounts

- PMLiVE

Ex-GSK head Witty to head group overseeing UK fast-track scheme

Medicines selected for the AAP could be made available much earlier

- PMLiVE

Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

Women on Kisqali were found to have a longer PFS than those on hormonal therapy alone

- PMLiVE

GSK to replace R&D head Vallance with Calico’s Hal Barron

Barron will also hold an executive director position on GSK’s board

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links